Elverum

Researchers are evaluating the clinical benefit of combining Navlimetostat BMS-986504, a selective MTA-cooperative inhibitor of PRMT5, with pembrolizumab and chemotherapy compared to placebo plus pembrolizumab and chemotherapy. This study focuses on participants with first-line metastatic non-small cell lung cancer NSCLC who have a homozygous MTAP deletion. The trial is a randomized Phase 23 study aimed at advancing treatment options for this specific lung cancer group. Participants will receive one of several combinations Navlimetostat plus pembrolizumab and chemotherapy, or placebo plus pembrolizumab and chemotherapy. Chemotherapy drugs involved may include cisplatin, carboplatin, pemetrexed, paclitaxel, or nab-paclitaxel, given at specified doses on certain days. The study uses a quadruple-masked, parallel design with multiple treatment arms to compare these regimens. During the study, participants will be monitored for progression-free survival and overall survival up to five years. Researchers will assess tumor response, disease control, duration and time to response, and safety through adverse event reporting and laboratory tests. The study includes detailed follow-up to evaluate efficacy and safety outcomes over the long term, with a primary completion date in 2031.

Researchers are evaluating a complex intervention to improve advance care planning ACP for severely ill elderly people living at home who are acutely admitted to hospital. This cluster randomized study involves twelve Norwegian geriatric hospital units and aims to enhance patient and family involvement in treatment decisions, improve quality of life, and support ethical and legal care planning. The project also explores barriers and facilitators to implementing ACP at clinical, health service, and governmental levels, including economic analyses. The intervention group receives a comprehensive support program that includes leadership commitment, training for staff, implementation teams, ACP coordinators, and practical tools such as guidelines and documentation templates. The control group receives no implementation support during the trial but will be offered the program afterward. The study period includes baseline, 9-month, and 18-month assessments for the intervention group and baseline and 18-month assessments for the control group. Participants will undergo questionnaires and interviews with patients, relatives, clinicians, and staff at multiple time points before, during, and after the implementation. Data from patient records and national health registers will be collected to assess the fidelity of ACP implementation, clinical outcomes, communication quality, and cost-effectiveness. The trial runs until December 2026 and includes various measures to evaluate the impact of the support program on ACP delivery and related outcomes.

Ankle fractures are common injuries occurring in about 1 in 800 people each year. This research evaluates whether repairing the deltoid ligament in unstable ankle fractures improves joint stability, functional outcomes, and may help prevent long-term osteoarthritis. The study focuses on patients with severe ankle fractures, as these injuries can significantly reduce daily function and affect the ability to work, potentially increasing community healthcare costs. Participants will be randomly assigned to one of two groups one receiving standard treatment involving plate and screw fixation of the lateral malleolus only, and the other receiving the same standard treatment plus an additional surgical repair suture of the deep deltoid ligament. The ligament repair involves a specific surgical technique where the ligament is reattached to an anchor in the talus. This multicenter randomized controlled study aims to compare these approaches in unstable Weber B ankle fractures. During the study, participants will be evaluated through patient-reported functional outcomes and radiological stability measurements at 1 and 2 years after injury, with functional outcome data also collected at 5 years. Additional assessments include general health, pain levels, ankle arthritis development, and foot and ankle function scores collected at various intervals up to 5 years. Researchers will monitor the long-term effects of ligament repair on ankle stability and function, with follow-up visits planned to assess recovery and outcomes.